Zevra Therapeutics, Inc.
NASDAQ:ZVRABiotechnology
+$0.31 today
- Market cap
- $552.20M
- Beta
- 0.89
- P/E (TTM)
- 6.1
- EPS (TTM)
- $2.13
Volume 0.62M
Average 1.43M
ZVRA Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Zevra Therapeutics, Inc.NASDAQ: ZVRA
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue grows, but more slowly than its trailing trend
Q1 FY2026 revenue of $36.22M rose 77.5% year over year, behind the +201.3% change in trailing-twelve-month revenue. Sequentially, it rose 6.1% from the prior quarter. Over 3 fiscal years it compounded at +118.8% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 7 analysts of $153.7M (+44.4%) for the fiscal year ending Dec 2026, a slowdown from the +350.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $36.22M+6.1% QoQ
- Last fiscal yearDec 2025
- $106.47M+350.9% YoY
- LTMMar 2026
- $122.29M+201.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +77.5% | +30.9% | -46.6 pp |
| 1 year | +350.9% | +44.4% | -306.6 pp |
| 3-year CAGR | +118.8% | +25.8% | -93.0 pp |
| 5-year CAGR | +22.4% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 106.47M USD
- Year-over-year change
- +350.9%
- 4-year CAGR
- +38.8%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 106.47M | +350.9% |
| FY2024 | 2024-12-31 | 23.61M | -14.0% |
| FY2023 | 2023-12-31 | 27.46M | +170.3% |
| FY2022 | 2022-12-31 | 10.16M | -64.5% |
| FY2021 | 2021-12-31 | 28.65M | — |
Revenue vs competitors
How ZVRA compares with its peers on the latest reported figures
- ZVRA's LTM Mar 2026 revenue of $122.29M is the 5th highest of the 11 companies compared; the peer median is $0.
- Its year-over-year change of +201.3% is the highest of 7, against a peer median of +14.4%.
- Over three fiscal years its annual growth of +118.8% compares with a peer median of +5.3%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | $4.72B | +13.5% | +5.3% | |
| LTM Sep 2026 | $3.7B | +38.0% | +24.3% | |
| LTM Sep 2026 | $1.75B | +15.3% | +9.9% | |
| LTM Jun 2026 | $830.44M | +24.9% | +2.5% | |
| LTM Mar 2026 | $122.29M | +201.3% | +118.8% | |
| LTM Sep 2026 | $0 | -100.0% | — | |
| LTM Sep 2026 | $0 | -100.0% | -7.4% | |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $0 | — | — |
| Peer median (excluding ZVRA) | $0 | +14.4% | +5.3% | |
Competitors are the stored peer set for ZVRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 28.65M | 10.16M | 27.46M | 23.61M | 106.47M |
| Cost of Revenue | 2.06M | 222K | 2.95M | 7.42M | 16.48M |
| Gross Profit | 26.59M | 9.94M | 24.52M | 16.2M | 89.99M |
| Gross Margin | 92.8% | 97.8% | 89.3% | 68.6% | 84.5% |
| Research & Development | 10.16M | 19.8M | 39.81M | 42.1M | 12.74M |
| Selling, General & Admin | 8.7M | 15.04M | 35.09M | 54.87M | 77.62M |
| Operating Expenses | 18.86M | 52.5M | 74.12M | 103.2M | 94.22M |
| Depreciation & Amortization | 257K | 944K | 1.01M | 6.39M | 4.05M |
| EBITDA | (7.89M) | (25.53M) | (43.54M) | (76.4M) | 98.71M |
| EBITDA Margin | -27.5% | -251.2% | -158.6% | -323.6% | 92.7% |
| Operating Income | 7.73M | (42.57M) | (49.6M) | (87M) | (4.23M) |
| Operating Margin | 27.0% | -418.9% | -180.6% | -368.5% | -4.0% |
| Interest Income | 261K | 1.51M | 4.54M | 2.18M | 6.95M |
| Interest Expense | 376K | 335K | 1.5M | 7.35M | 7.98M |
| Other Income / Expenses | (16.25M) | 15.76M | 3.56M | (3.14M) | 90.91M |
| Income Before Tax | (8.52M) | (26.81M) | (46.05M) | (90.14M) | 86.68M |
| Pre-Tax Margin | -29.7% | -263.8% | -167.7% | -381.8% | 81.4% |
| Income Tax Expense | 34K | (33K) | 0 | 15.37M | 3.45M |
| Net Income | (8.56M) | (26.77M) | (46.05M) | (105.51M) | 83.23M |
| Net Margin | -29.9% | -263.5% | -167.7% | -446.9% | 78.2% |
| EPS (Basic) | (2.11) | (0.78) | (1.30) | (2.28) | 1.40 |
| EPS (Diluted) | (2.11) | (0.78) | (1.30) | (2.28) | 1.35 |
| Weighted Avg Shares | 29.77M | 34.49M | 35.45M | 46.25M | 55.31M |
| Weighted Avg Shares (Diluted) | 29.77M | 34.49M | 35.45M | 46.25M | 57.26M |
Zevra Therapeutics, Inc.
NASDAQ:ZVRA
Intrinsic Alpha fair value
Locked
Current Price
$9.28
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.